Abstract
Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.
| Original language | English |
|---|---|
| Pages (from-to) | 320-328 |
| Number of pages | 9 |
| Journal | International Clinical Psychopharmacology |
| Volume | 30 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2015 Oct 1 |
Fingerprint
Keywords
- Atypical antipsychotics
- Long-acting injectable antipsychotics
- Medication Satisfaction Questionnaire
- Paliperidone palmitate
- Schizophrenia
- Treatment Satisfaction Questionnaire for Medication
ASJC Scopus subject areas
- Psychiatry and Mental health
- Pharmacology (medical)
Cite this
Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics. / Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; Lee, Sang Ick; Chang, Jae Seung; Choi, Jung Seok; Lee, Heon-Jeong; Cho, Seong Jin; Jun, Tae Youn; Lee, Seung Hwan; Han, Changsu; Lee, Kyoung Uk; Lee, Kyung Kyu; Lee, Eunjung.
In: International Clinical Psychopharmacology, Vol. 30, No. 6, 01.10.2015, p. 320-328.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics
AU - Kwon, Jun Soo
AU - Kim, Sung Nyun
AU - Han, Jaewook
AU - Lee, Sang Ick
AU - Chang, Jae Seung
AU - Choi, Jung Seok
AU - Lee, Heon-Jeong
AU - Cho, Seong Jin
AU - Jun, Tae Youn
AU - Lee, Seung Hwan
AU - Han, Changsu
AU - Lee, Kyoung Uk
AU - Lee, Kyung Kyu
AU - Lee, Eunjung
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.
AB - Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone. The Medication Satisfaction Questionnaire (MSQ) and the Treatment Satisfaction Questionnaire for Medication (TSQM) were used to evaluate patient satisfaction with treatment, whereas the Positive and Negative Syndrome Scale (PANSS) and the Personal and Social Performance (PSP) scale were used to evaluate efficacy. From baseline to the final assessment, the MSQ score increased significantly in both groups, and the increase was greatest after the first administration of paliperidone palmitate in the immediate switch group. The scores of TSQM effectiveness, convenience, and global satisfaction as well as the PSP total score increased significantly, whereas the PANSS total score decreased significantly in both groups. The immediate switch group showed a significant improvement in the TSQM convenience score compared with the delayed switch group on oral antipsychotics during the comparison period. Most adverse events were minor and tolerable. In short, switching from oral atypical antipsychotics to paliperidone palmitate because of poor satisfaction significantly improved patient satisfaction, with comparable efficacy and tolerability.
KW - Atypical antipsychotics
KW - Long-acting injectable antipsychotics
KW - Medication Satisfaction Questionnaire
KW - Paliperidone palmitate
KW - Schizophrenia
KW - Treatment Satisfaction Questionnaire for Medication
UR - http://www.scopus.com/inward/record.url?scp=84942750247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942750247&partnerID=8YFLogxK
U2 - 10.1097/YIC.0000000000000093
DO - 10.1097/YIC.0000000000000093
M3 - Article
C2 - 26196188
AN - SCOPUS:84942750247
VL - 30
SP - 320
EP - 328
JO - International Clinical Psychopharmacology
JF - International Clinical Psychopharmacology
SN - 0268-1315
IS - 6
ER -